Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R&D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more

JAMA Editor’s Summary

Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R&D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the

March 3, 2020

Listen on your favorite player Take me to this show’s page

Newer →

Permissive Hypotension in ICU Patients, POLST and ICU Admissions, USPSTF HCV Screening Recommendations, and more

← Older

Interferon β1a for ARDS, Microaxial LVAD vs IABP for Cardiogenic Shock, Abbreviated Breast MRI vs DBT for Breast Cancer Screening, Screening for Cognitive Impairment, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R&D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 3, 2020 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00